1. Dajee H, Hurley EJ, Szarnicki RJ. Cardiac valve
replacement in systemic lupus erythematosus. A
review. J Thorac Cardiovasc Surg 1983; 85: 718-726.
2. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart
valve involvement (Libman–Sacks endocarditis) in the
antiphospholipid syndrome. Circulation 1996; 93:
1579-1587.
3. Kumar S, Sinha B, Ravikumar E. Emergency aortic
valve replacement in systemic lupus erythematosus.
Heart Lung Circ 2006; 15: 397-399.
4. Knockaert DC. Cardiac involvement in systemic
inflammatory diseases. Eur Heart J 2007; 28: 1797-
1804.
5. Nobrega TP, Klodas E, Breen JF, et al. Giant coronary
artery aneurysms and myocardial infarction in a
patient with systemic lupus erythematosus. Cathet
Cadiovasc Diagn 1996; 39: 75-79.
6. Sharma AK, Farb A, Maniar P, et al. Spontaneous coronary
artery dissection in a patient with systemic lupus
erythematosis. Hawaii Med J 2003; 62: 248-253.
7. Schattner A, Liang MH. The cardiovascular burden of
lupus: a complex challenge. Arch Intern Med 2003;
163: 1507-1510.
8. Asanuma Y, Oeser A, Shintani AK, et al. Premature
coronary-artery atherosclerosis in systemic lupus erythematosus.
N Engl J Med 2003; 349: 2407-2415.
9. Boumpas DT, Austin HA III, Fessler BJ, et al. Systemic
lupus erythematosus: emerging concepts. Ann Intern
Med 1995; 122: 940-950.
10. Hahn BH. Systemic lupus erythematosus and accelerated
atherosclerosis. N Engl J Med 2004; 349: 2379-
2380.
11. Roman MJ, Shanker BA, Davis A, et al. Prevalence and
correlates of accelerated atherosclerosis in systemic
lupus erythematosus. N Engl J Med 2003; 349:
2399–2406.
12. Roldan CA, Shively BK, Crawford MH. An
Echocardiographic Study of Valvular Heart Disease
Associated with Systemic Lupus Erythematosus. N Engl
J Med 1996; 335: 1424-1430.
13. Khamashta MA, Cervera R, Asherson RA, et al.
Association of antibodies against phospholipids with
heart valve disease in systemic lupus erythematosus.
Lancet 1990; 335: 1541-1544.
14. Jonsson CA, Svensson L. Beneficial effect of the inosine
monophosphate Dehydrogenase inhibitor
mycophenolate mofetil on survival and severity of
glomerulonephritis in systemic lupus erythematosus
(SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol 1999;
116: 534-541.
